Agilon Health (NYSE:AGL) Given New $1.50 Price Target at Wells Fargo & Company

Agilon Health (NYSE:AGL) had its price objective hoisted by Wells Fargo & Company from $1.00 to $1.50 in a report released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

AGL has been the topic of several other research reports. BTIG Research reaffirmed a “neutral” rating on shares of Agilon Health in a research report on Friday, December 12th. Barclays decreased their target price on Agilon Health from $1.00 to $0.50 and set an “underweight” rating for the company in a research report on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Finally, Royal Bank Of Canada raised shares of Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $2.60.

Agilon Health Price Performance

AGL traded down $0.01 on Friday, reaching $0.58. The company’s stock had a trading volume of 2,024,525 shares, compared to its average volume of 7,721,225. Agilon Health has a 1 year low of $0.34 and a 1 year high of $6.08. The business’s 50 day moving average is $0.71 and its 200 day moving average is $0.86. The stock has a market cap of $241.87 million, a price-to-earnings ratio of -0.61 and a beta of 0.06.

Agilon Health (NYSE:AGL) last announced its earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). Agilon Health had a negative net margin of 6.60% and a negative return on equity of 100.06%. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.46 billion. As a group, research analysts forecast that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Several large investors have recently modified their holdings of AGL. CenterBook Partners LP lifted its holdings in shares of Agilon Health by 492.4% during the third quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock valued at $11,771,000 after purchasing an additional 9,499,012 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Agilon Health by 1,028.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 789,703 shares of the company’s stock worth $1,816,000 after buying an additional 719,751 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Agilon Health by 2.6% in the second quarter. Geode Capital Management LLC now owns 7,156,466 shares of the company’s stock worth $16,462,000 after buying an additional 178,477 shares during the period. SG Americas Securities LLC increased its position in shares of Agilon Health by 60.1% in the second quarter. SG Americas Securities LLC now owns 230,912 shares of the company’s stock worth $531,000 after acquiring an additional 86,723 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of Agilon Health by 583.2% during the second quarter. XTX Topco Ltd now owns 400,760 shares of the company’s stock valued at $922,000 after acquiring an additional 342,100 shares during the period.

Agilon Health News Summary

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Q4 revenue beat estimates — Agilon reported $1.57B in revenue versus the $1.46B consensus, showing top-line resilience for the quarter. MarketBeat/press release
• Positive Sentiment: Company outlined a 2026 target of roughly $5.5B revenue and breakeven adjusted EBITDA, signaling management expects stabilization as it executes its transformation and disciplined contracting strategy. Seeking Alpha article
• Neutral Sentiment: Management made supporting materials available (conference call, slide deck) for investors to assess quarter details and longer-term plan execution; review these for detail on membership, margin levers and timing. Slide deck / conference call
• Negative Sentiment: Earnings miss and profitability concerns — Agilon reported a ($0.46) EPS, missing the ($0.27) consensus by $0.19 and showing a negative net margin and ROE, which fuels short-term downside pressure. MarketBeat earnings summary
• Negative Sentiment: Guidance came in below Street expectations — FY‑2026 revenue guidance ($5.4B–$5.6B) and Q1 revenue guidance missed consensus (~$6.0B and $1.5B expectations respectively), increasing execution risk and prompting investor caution. Press release / guidance
• Negative Sentiment: Analyst downgrade — Barclays cut its price target to $0.50 and set an “underweight” rating, signaling further near-term downside versus recent levels and likely contributing to selling pressure. Benzinga note
• Negative Sentiment: Multiple securities-class-action filings and many law firms are soliciting lead plaintiffs (deadline Mar. 2, 2026), raising litigation risk and potential future legal costs or settlements that can weigh on the stock. Representative notices from firms include Rosen, Schall, Pomerantz, Faruqi and others. GlobeNewswire class action notice

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.